Ypsomed has concluded a long-term supply agreement with Novo Nordisk for large quantities of autoinjectors. The autoinjectors will be used to administer drugs for the self-treatment in various metabolic indications.
Natural Cycles, the company that developed the world’s first birth control app, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its use of wrist temperature data from Apple Watch.
Dr. Samir Acharya, Dr. Rajiv Vaidya and Cyrill Kellerhals from Andelyn Biosciences discuss the trends in the field of C> and explore the current and future challenges facing C> developers and manufacturers as well as solutions to overcome.
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved Jardiance (empagliflozin) for the treatment of adults with chronic kidney disease (CKD), Boehringer Ingelheim and Eli Lilly and Company announced.
Regulatory authorities have been focusing on safeguarding global supply chains. Juan Torrijos Lopez, GMP consultant at Rephine provides some practical pointers as to how pharmaceutical manufacturers should respond to evolving expectations.
Responsible Manufacturing Can Help Curb Drug Resistance: New report sets out clear steps pharmaceutical companies should take to limit AMR risk in antibiotic production.
Ascendis Pharma and Phillips-Medisize Receive Third Award for the SKYTROFA Auto-Injector. his first-of-its-kind product enables convenient and efficient preparation and delivery of SKYTROFA—a vital growth hormone treatment for children.
Dr. Peter Hamley, Chief Scientific Officer at Samsara Therapeutics, explores whether developments in therapeutics for neurodegenerative diseases are truly disease modifying or addressing the symptoms of a deeper problem.
As the costs and resourcing challenges of hospital-based cancer care continue to grow, Dr Toby Basey-Fisher, CEO & founder of Entia, explains why implementing robust home-based patient support programmes is a win-win for pharmaceutical companies.
